Cardiovascular-Renal Consequences of Reducing Renal Mass After Living Kidney Donation
NCT ID: NCT01564966
Last Updated: 2012-03-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
46 participants
OBSERVATIONAL
2008-04-30
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Live-donor kidney transplantation is generally considered the best choice for patients who have renal failure and are awaiting transplantation, because these kidneys function better than kidneys from deceased donors, and waiting times for deceased-donor transplants are long
* Although several studies have shown that kidney donation has low short-term morbidity and mortality, the data on long-term outcomes are much less complete.
* This study is designed to prospectively evaluate the effects of unilateral nephrectomy on cardiovascular-renal functions of donors after living kidney donation: the development of hypertension, albuminuria, renal failure, inflammatory and endothelial changes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Different Vascular and Renal Parameters in Living Kidney Donors
NCT06056466
Risk of Acute Kidney Injury in Living Liver Donor Surgery
NCT05255510
Recurrent Glomerulonephritis After Renal Transplantation
NCT02700516
Effect of Obesity on Long-term Clinical Outcomes After Kidney Donation
NCT01368822
Impact of %6 HES 130/0.4 and %4 Gelofusine Infusion on Kidney Function in the Living-donor Liver Transplantation
NCT02079350
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Live-donor kidney transplantation is generally considered the best choice for patients who have renal failure and are awaiting transplantation, because these kidneys function better than kidneys from deceased donors, and waiting times for deceased-donor transplants are long. Although several studies have shown that kidney donation has low short-term morbidity and mortality, the data on long-term outcomes are much less complete. The short and long term renal functions of donors after kidney donation were much studied and still remain uncertain, the cardiovascular effects of reduction in renal mass in kidney donors is also not clearly known.
* Endothelial dysfunction (ED) is the first step for subsequent development of atherosclerosis, which can help us to assess the cardiovascular changes after kidney donation. Prospectively examining the endothelial consequences of uninephrectomy in donors may provide useful insight into the existence and pathophysiology of cardiovascular disease in donors and, therefore, into how the cardiovascular disease risk associated with renal impairment might eventually be reduced.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Living kidney donors
Those who donate kidneys
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ages of 18 and 70
* Creatinine clearance at donation \> 80 ml/min/1.73 m2
Exclusion Criteria
* Diabetes mellitus
* Hypertension
* Valvular heart disease, any prior coronary intervention
* Congestive heart failure (New York Heart Association class II or greater)
* Cardiac arrhythmia
* A history of cerebral infarction or transient ischemic attack
* Active infection or non-infectious overt inflammation
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istanbul University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yasar Caliskan
Specialist of Nephrology, MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alaattin Yildiz, Professor of Medicine, MD
Role: STUDY_DIRECTOR
Istanbul University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4369
Identifier Type: OTHER
Identifier Source: secondary_id
20120209
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.